source
- FDA says Capricor's DMD cell therapy failed to meet Phase 3 endpointsThe FDA briefing documents released before an advisory committee meeting state that the Phase 3 trial of Capricor's deramiocel did not achieve its pre-specified primary and secondary efficacy endpo…
- Sarepta appoints former AbbVie R&D chief Michael Severino as new CEO amid DMD regulatory outlookSarepta Therapeutics announced that Michael Severino, who previously led Tessera Therapeutics and served as AbbVie’s head of research and development, will become the company’s chief executive. Sev…